- Home
- TYGO vs IVVD Comparison
TYGO vs IVVD Comparison
Compare TYGO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- IVVD
- Stock Information
- Founded
- TYGO 2007
- IVVD 2020
- Country
- TYGO United States
- IVVD United States
- Employees
- TYGO N/A
- IVVD N/A
- Industry
- TYGO Semiconductors
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- IVVD Health Care
- Exchange
- TYGO Nasdaq
- IVVD Nasdaq
- Market Cap
- TYGO 58.9M
- IVVD 66.6M
- IPO Year
- TYGO N/A
- IVVD 2021
- Fundamental
- Price
- TYGO $0.97
- IVVD $0.41
- Analyst Decision
- TYGO Buy
- IVVD Strong Buy
- Analyst Count
- TYGO 3
- IVVD 4
- Target Price
- TYGO $3.00
- IVVD $7.89
- AVG Volume (30 Days)
- TYGO 321.1K
- IVVD 1.9M
- Earning Date
- TYGO 02-11-2025
- IVVD 11-14-2024
- Dividend Yield
- TYGO N/A
- IVVD N/A
- EPS Growth
- TYGO N/A
- IVVD N/A
- EPS
- TYGO N/A
- IVVD N/A
- Revenue
- TYGO $45,985,000.00
- IVVD $11,564,000.00
- Revenue This Year
- TYGO N/A
- IVVD N/A
- Revenue Next Year
- TYGO $57.24
- IVVD $486.65
- P/E Ratio
- TYGO N/A
- IVVD N/A
- Revenue Growth
- TYGO N/A
- IVVD N/A
- 52 Week Low
- TYGO $0.76
- IVVD $0.38
- 52 Week High
- TYGO $2.12
- IVVD $5.20
- Technical
- Relative Strength Index (RSI)
- TYGO 53.32
- IVVD 38.26
- Support Level
- TYGO $0.76
- IVVD $0.38
- Resistance Level
- TYGO $0.89
- IVVD $0.50
- Average True Range (ATR)
- TYGO 0.17
- IVVD 0.07
- MACD
- TYGO -0.00
- IVVD 0.00
- Stochastic Oscillator
- TYGO 24.37
- IVVD 11.73
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.